# Alport Syndrome

Confirm suspected Alport syndrome with COL4A3, COL4A4, and COL4A5 testing, define inheritance and renal risk, initiate renin-angiotensin system blockade when indicated, and identify relatives requiring surveillance before proteinuria and progressive kidney dysfunction develop.

**Clinical question:** How should physicians diagnose, risk-stratify, treat, and screen families affected by Alport syndrome?

Updated: 2026-08-24T17:46:07.447235+00:00

## What matters in practice
- Order molecular testing for COL4A3, COL4A4, and COL4A5 in persistent glomerular hematuria, particularly with family kidney disease, hearing loss, or characteristic ocular findings; a negative pedigree does not exclude Alport syndrome. [10][17]
- Use the molecular result to establish the diagnosis, determine X-linked, autosomal recessive, autosomal dominant, or digenic inheritance, and direct cascade testing. [2][17][18]
- Proteinuria marks progressive renal disease; RAAS blockade is established management, and ramipril delayed proteinuria onset in a prospective pediatric trial. [2][10][12]
- Males with X-linked disease and patients of either sex with autosomal recessive disease generally have greater kidney-failure risk than females with X-linked disease or individuals with autosomal dominant disease. [4][18]
- Do not dismiss monoallelic pathogenic or likely pathogenic COL4A3/COL4A4 findings as benign familial hematuria: CKD, focal segmental glomerulosclerosis, and kidney failure can occur, although absolute kidney-failure risk remains uncertain. [11][19]

## When persistent glomerular hematuria warrants collagen IV testing

Treat persistent glomerular hematuria as a genetic-kidney-disease signal when the phenotype or family history is compatible.

Order a molecular panel that includes COL4A3, COL4A4, and COL4A5 for persistent glomerular hematuria with any of the following: a family history of hematuria, CKD, kidney failure, sensorineural hearing loss, anterior lenticonus, or maculopathy. Absence of hearing, ocular, or family-history clues does not exclude a collagen IV disorder and should not defer testing when isolated glomerular hematuria persists. [10][17]

A pathogenic variant or variants in COL4A3, COL4A4, or COL4A5 in a patient with suggestive findings establishes a molecular diagnosis. A multigene kidney-disease panel is preferable when the phenotype is not definitive because it simultaneously evaluates the three collagen IV genes and competing inherited causes of glomerular hematuria. [17]

Use kidney biopsy selectively rather than as the default confirmation test. Electron microscopy and collagen IV alpha-chain immunostaining can support diagnosis when genetic testing is unavailable or uninformative; skin alpha5(IV) immunostaining is an additional option in selected X-linked cases. Biopsy remains particularly useful when the clinical course suggests a superimposed glomerular disease. [10][17][19]
- Document urinalysis, albuminuria or proteinuria, blood pressure, serum creatinine with estimated GFR, and pedigree before counseling on inheritance and renal trajectory. Progressive disease characteristically evolves from microhematuria to proteinuria and then declining kidney function. [2][18]
- Obtain formal audiologic and ophthalmologic evaluation when Alport syndrome is diagnosed or strongly suspected; bilateral high-frequency sensorineural hearing loss, anterior lenticonus, and perimacular flecks increase phenotypic confidence. [2][3][10]

*Diagnostic pathways for suspected Alport syndrome. [10][17][19]*

| Clinical scenario | Next diagnostic action | Interpretation and consequence |
| --- | --- | --- |
| Persistent glomerular hematuria with kidney-disease pedigree, hearing loss, or ocular findings | Order molecular testing including COL4A3, COL4A4, and COL4A5. [10][17] | A pathogenic variant in a compatible phenotype establishes molecular diagnosis and enables inheritance-based counseling and cascade testing. [17][18] |
| Persistent isolated glomerular hematuria without family history or extrarenal features | Still obtain collagen IV genetic testing when suspicion persists. [10] | Negative family history and absent extrarenal manifestations do not exclude Alport syndrome. [10] |
| Genetic testing unavailable or uninformative | Consider kidney biopsy with electron microscopy and collagen IV alpha-chain immunostaining; consider skin alpha5(IV) staining in selected X-linked cases. [10][17] | Histology may support the diagnosis but can be ambiguous in phenotypically heterogeneous collagen IV disease. [10] |
| Monoallelic pathogenic or likely pathogenic COL4A3/COL4A4 variant with atypical proteinuria, CKD, or active urinary findings | Consider kidney biopsy to assess for a coexisting glomerular process. [19] | FSGS, CKD, and kidney failure may segregate with monoallelic variants, but another renal diagnosis can coexist. [11][19] |

## Use inheritance pattern to frame renal prognosis and family risk

Gene, zygosity, inheritance, sex, and variant type are the principal available prognostic discriminators.

Classify disease as X-linked COL4A5-related, autosomal recessive biallelic COL4A3/COL4A4-related, autosomal dominant monoallelic COL4A3/COL4A4-related, or digenic disease. For double heterozygous COL4A3/COL4A4 variants, determine whether variants are in cis or in trans: cis inheritance behaves as autosomal dominant, whereas trans inheritance is autosomal recessive. [2][3][4]

Counsel males with X-linked Alport syndrome and males and females with autosomal recessive disease that untreated renal disease commonly progresses through proteinuria and renal insufficiency to ESKD. Females with X-linked disease and individuals with autosomal dominant disease have more variable courses, with kidney failure often delayed into later adulthood; hearing loss is relatively later and ocular involvement less common in these groups. [4][18]

Interpret monoallelic COL4A3/COL4A4 results in the clinical context. Labels including thin basement membrane nephropathy, autosomal dominant Alport syndrome, type IV collagen-associated kidney disease, and Alport spectrum nephropathy have been used; the absolute risk of kidney failure from a heterozygous pathogenic or likely pathogenic autosomal variant remains poorly defined. [11][19]
- A COL4A5 pathogenic variant in a mother confers a 50% transmission probability in each pregnancy. [18]
- When both parents carry a heterozygous pathogenic COL4A3 or COL4A4 variant causing autosomal recessive disease, each pregnancy has a 25% probability of biallelic disease, 50% probability of heterozygosity, and 25% probability of neither familial variant. [18]
- Variant type modifies prognosis; protein-truncating variants are associated with more severe disease in autosomal recessive disease and in males with X-linked disease. [4]

*Inheritance-based clinical framing in Alport syndrome. [2][4][18]*

| Molecular category | Expected phenotype pattern | Clinical action |
| --- | --- | --- |
| X-linked COL4A5 disease | Males generally have more severe renal disease; females have variable expression and later kidney failure more often. [4][18] | Assess renal trajectory and proteinuria early; test at-risk relatives and provide X-linked reproductive counseling. [17][18] |
| Autosomal recessive COL4A3/COL4A4 disease | Males and females are at high risk for progressive renal disease and ESKD without treatment. [18] | Identify biallelic disease promptly, treat renal manifestations, and test siblings and parents for familial variants. [17][18] |
| Monoallelic COL4A3/COL4A4 disease | Phenotype ranges from hematuria to CKD, FSGS, and kidney failure; absolute kidney-failure risk is uncertain. [11][19] | Follow urine albumin, blood pressure, and kidney function; investigate discordant or accelerated disease for coexisting pathology. [19] |
| Digenic COL4A3/COL4A4 variants | Trans configuration is autosomal recessive; cis configuration is autosomal dominant. [2] | Establish phase when possible because inheritance classification changes family counseling and risk assessment. [2] |

## Treat progressive renal disease before loss of GFR

Proteinuria and hypertension should trigger antiproteinuric CKD management rather than observation alone.

Use an ACE inhibitor or ARB to reduce proteinuria and manage hypertension in proteinuric Alport syndrome; RAAS blockade is established standard management. In a prospective pediatric trial, ramipril delayed onset of proteinuria, an early marker of progressive kidney disease. [2][10][12][20]

For a heterozygous pathogenic or likely pathogenic COL4A3/COL4A4 variant, initiate RAAS blockade when albuminuria or additional risk factors for progression are present. Do not use the historically reassuring label “benign familial hematuria” to substitute for surveillance of albuminuria, blood pressure, and kidney function. [2][11][19]

Monitor serial urine albumin or protein excretion, blood pressure, serum creatinine, and estimated GFR after RAAS-blockade initiation and during dose adjustment. If kidney function progresses to kidney failure, plan dialysis or kidney transplantation; many affected patients ultimately require kidney replacement therapy despite delayed progression with current measures. [20]
- Do not combine an ACE inhibitor and ARB routinely on the basis of the limited Alport-specific evidence summarized here; current established therapy is RAAS blockade, not dual RAAS blockade. [2][12][20]
- SGLT2 inhibition is under prospective study in young patients with Alport syndrome; trial development should not be interpreted as established Alport-specific efficacy. [15]
- Sparsentan has shown renal and hearing benefits versus an ARB in an Alport mouse model, but this is preclinical evidence rather than a clinical treatment recommendation. [13]

### When proteinuria is absent

Continue structured surveillance because microhematuria may precede proteinuria and progressive kidney dysfunction. In patients at genetic risk whose familial variant is unknown, evaluate with urinalysis and blood-pressure measurement; use molecular testing when the familial pathogenic variant is known. [18]

*Renal management decisions in Alport syndrome. [2][10][12][18][20]*

| Finding | Action | Monitoring or escalation |
| --- | --- | --- |
| Proteinuria with Alport syndrome | Start RAAS blockade with an ACE inhibitor or ARB. [2][12][20] | Follow blood pressure, urinary protein or albumin, serum creatinine, and estimated GFR. [20] |
| Child with early Alport disease | Consider ramipril as the ACE inhibitor supported by prospective evidence for delaying proteinuria onset. [10] | Track development of proteinuria as a marker of renal progression. [10] |
| Heterozygous pathogenic or likely pathogenic COL4A3/COL4A4 variant plus albuminuria or progression risk factors | Use RAAS blockade. [2] | Monitor for CKD progression and reassess for another glomerular diagnosis if the phenotype is atypical. [19] |
| Progressive kidney failure | Prepare for dialysis or kidney transplantation. [20] | Coordinate kidney-failure planning while continuing family genetic evaluation. [17][20] |

## Screen hearing, vision, and relatives as part of renal management

Extrarenal assessment improves phenotypic definition, while cascade testing enables earlier renal surveillance and intervention.

Arrange audiology and ophthalmology assessment because bilateral high-frequency sensorineural hearing loss, anterior lenticonus, and perimacular flecks are clinically informative manifestations of collagen IV disease. Their presence supports the diagnosis, but their absence does not rule it out. [2][3][10]

Offer targeted molecular testing to at-risk relatives when the familial pathogenic variant is known. If it is not known, use urinalysis and blood-pressure evaluation to identify relatives requiring further assessment. Earlier identification is intended to permit surveillance and timely intervention before proteinuria and progressive renal disease emerge. [17][18]

Refer affected individuals and families for genetic counseling after a pathogenic result. Counseling should cover inheritance pattern, reproductive transmission risk, variable expression in females with X-linked disease and monoallelic autosomal disease, and the implications of testing relatives who may have isolated hematuria. [2][17][18]
- Evaluate potential kidney donors within affected families with molecular testing when a familial pathogenic variant is known. [17]
- Include nephrology, genetics, audiology or otolaryngology, and ophthalmology according to renal stage and manifestations. [20]
- When kidney biopsy is performed for suspected superimposed disease in a monoallelic COL4A3/COL4A4 carrier, integrate pathology with the genetic result rather than assuming all proteinuria reflects collagen IV disease. [19]

*Family evaluation and extrarenal care. [2][17][18][20]*

| Clinical task | Preferred action | Reason for action |
| --- | --- | --- |
| Known familial pathogenic variant | Offer targeted molecular testing to at-risk relatives. [17][18] | Identifies relatives who need surveillance and early renal intervention. [17] |
| Familial variant not established | Perform urinalysis and blood-pressure assessment in at-risk relatives. [18] | Detects renal manifestations requiring genetic evaluation or nephrology follow-up. [18] |
| Auditory phenotype | Obtain formal audiologic assessment. [2][10] | High-frequency sensorineural hearing loss is a recognized Alport manifestation. [2] |
| Ocular phenotype | Obtain ophthalmologic evaluation for anterior lenticonus and macular abnormalities. [2][10] | Characteristic eye findings refine the clinical phenotype. [2][10] |

## References
1. Human umbilical cord mesenchymal stem cell therapy for ... — bmjopen.bmj.com — https://bmjopen.bmj.com/content/14/3/e075138
2. The 2019 and 2021 International Workshops on Alport Syndrome | European Journal of Human Genetics — www.nature.com — https://www.nature.com/articles/s41431-022-01075-0
3. Alport Syndrome — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2949813924000478
4. Alport Syndrome: Clinical Spectrum and Therapeutic Advances — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2590059523000407
5. Alport Syndrome Classification and Management — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2590059520301606
6. Applying the Alport Variant Collaborative guidelines in the ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1888970024000422
7. Expert Guidelines for the Management of Alport Syndrome ... — journals.lww.com — https://journals.lww.com/JASN/_layouts/15/oaks.journals/downloadpdf.aspx?an=00001751-201303000-00008
8. A COL4A4-G394S Variant and Impaired Collagen IV... — journals.lww.com — https://journals.lww.com/kidney360/fulltext/2022/11000/a_col4a4_g394s_variant_and_impaired_collagen_iv.13.aspx
9. Ocular Manifestations and Potential Treatments of Alport ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2022/9250367
10. Genetic testing and glomerular hematuria—A nephrologist's perspective - Kashtan - 2022 - American Journal of Medical Genetics Part C: Seminars in Medical Genetics - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ajmg.c.31987
11. Diagnosis, management and treatment of the Alport syndrome – 2024 guideline on behalf of ERKNet, ERA and ESPN | Nephrology Dialysis Transplantation | Oxford Academic — academic.oup.com — https://academic.oup.com/ndt/article/40/6/1091/7915083
12. Study Design and Baseline Characteristics of the... : American Journal of Nephrology — journals.lww.com — https://journals.lww.com/00078825-202103000-00003
13. Dual inhibition of the endothelin and angiotensin... : The Journal of Pathology — journals.lww.com — https://journals.lww.com/01445513-202306000-00010
14. 623 SGLT2 inhibitors in adult patients with Alport syndrome — academic.oup.com — https://academic.oup.com/ndt/article-abstract/40/Supplement_3/gfaf116.011/8294644
15. Protocol and rationale for a randomized controlled SGLT2 ... — academic.oup.com — https://academic.oup.com/ndt/article/40/4/679/7731148
16. KHI Innovation Conference Highlights Patient- Centered Care — www.asn-online.org — https://www.asn-online.org/publications/kidneynews/archives/2026/KN_2026_07_jul.pdf
17. Alport Syndrome - GeneReviews® - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/n/gene/alport
18. Alport Syndrome - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pubmed/20301386
19. Diagnosis, management and treatment of the Alport syndrome – 2024 guideline on behalf of ERKNet, ERA and ESPN - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12209846
20. Alport Syndrome - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK470419
21. [PDF] Kidney News - August 2019 - American Society of Nephrology — www.asn-online.org — https://www.asn-online.org/publications/kidneynews/archives/2019/KN_2019_08_aug.pdf
22. Kidney News - August 2020 — www.asn-online.org — https://www.asn-online.org/publications/kidneynews/archives/2020/KN_2020_08_aug.pdf
23. Update on Alport Syndrome: The Report of the 2024 ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2468024926000161
24. Clinical and Genetic Features of Autosomal Dominant ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0272638621005059

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.